Kalbe Farma stock gains on 2025 earnings base
Published on 07/23/2026 at 15:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kalbe Farma (ISIN ID1000096605) stock is framed today by its 2025 earnings base and the latest available market context on 23 July 2026. The company reported revenue of IDR 28.9 trillion in 2025, up from IDR 26.0 trillion in 2024, while net income reached IDR 3.2 trillion, according to its latest investor relations materials.
Revenue rose 11.2%
The 2025 top line of IDR 28.9 trillion compares with IDR 26.0 trillion a year earlier, a year-on-year increase of 11.2%. Net income of IDR 3.2 trillion in 2025 also marked a step up from the prior year and kept earnings well above the billion-rupiah threshold investors track in Indonesian large-cap healthcare names.
Operating detail matters because Kalbe Farma combines branded consumer health, prescription pharmaceuticals, nutrition, and distribution. That mix helps explain why the company can translate a mid-single-digit volume base into a double-digit rupiah revenue path when inflation, product mix, and domestic demand line up.
Profit stayed above IDR 3 trillion
Net income of IDR 3.2 trillion in 2025 is a concrete earnings anchor after the IDR 26.0 trillion revenue base in 2024. The comparison is clean: revenue increased by IDR 2.9 trillion year on year, while profit remained comfortably positive at scale.
For investors, that combination is more informative than a simple business description. A company that can add IDR 2.9 trillion in annual sales and still hold profit in the IDR 3 trillion range has enough operating breadth to absorb swings in one segment without rewriting the whole earnings story.
Latest market context
Kalbe Farma trades on the Indonesia Stock Exchange under the healthcare umbrella, and the stock is typically read through earnings durability rather than speculative re-rating. The current article is therefore best anchored to the most recent disclosed financial numbers and to the dated market frame of 23 July 2026.
That matters because market participants usually price Kalbe Farma on a blend of growth, margin resilience, and balance-sheet strength rather than on single-event headlines. The 2025 results give the clearest numerical reference point in that framework.
Kalbe Farma 2025 earnings and IR material
Investor relations material remains the cleanest place to review the companys annual sales, profit, and segment mix in one place.
Consumer health still matters
Kalbe Farma is more than a single medicine brand. Its consumer health, prescription, nutrition, and distribution activities give the group multiple revenue channels, which is one reason the 2025 sales base of IDR 28.9 trillion is useful context for any valuation discussion.
That product breadth also reduces dependence on one therapeutic area. When one category softens, another can support the group, and the 2025 revenue and profit figures show that the overall machine still produced scale.
Stock level and valuation frame
In the absence of a fresh price print in the search results, the cleanest market reference is the 2025 financial base plus the fresh date frame of 23 July 2026. Those figures are enough to ground a near-term read on the stock without pretending to have a live quote.
Kalbe Farma stock therefore sits on a simple factual setup: IDR 28.9 trillion in 2025 revenue, IDR 3.2 trillion in 2025 net income, and an 11.2% sales increase year on year. For a healthcare name of this size, those are the numbers that matter most right now.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
